Fluquadri

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Fluquadri

Property Description
Active ingredient Influenza virus haemagglutinin (Split Virion)
Form Suspension for Injection
Pharmacological class Vaccine
Common use Prevention of influenza disease (seasonal flu)
Origin Biological (Egg-based vaccine)

The Identity and Class of Fluquadri

Fluquadri is an inactivated quadrivalent influenza vaccine intended for active immunisation to achieve the prevention of influenza disease. It is classified within the pharmacological group of Vaccines and is clinically recognized for use in individuals 6 months of age and older. The product is provided as a sterile suspension for injection, designed for intramuscular (IM) administration. As an inactivated preparation, it contains purified viral fragments and is incapable of causing the flu illness itself.

Composition and the Quadrivalent Advantage

The core of Fluquadri's makeup is its combination product status, defined by its quadrivalent formulation which targets four distinct virus components. Its active ingredients are the purified influenza virus haemagglutinin antigens from Four Split Influenza Virus, Inactivated Strains: two Influenza A subtypes and two Influenza B lineages. The quadrivalent configuration is a key feature, providing coverage for both major B-lineages, a factor considered relevant when predicting seasonal viral circulation. The specific strains included are updated annually based on surveillance data and international health recommendations.

Core Purpose: Targeted Immunization

The overall purpose of Fluquadri is to initiate the body's protective response, a process known as active immunisation. By presenting the viral antigens to the immune system, the vaccine stimulates antibody production and immunological memory. This mechanism equips the body with a targeted defense against the four particular strains included in the annual formulation, thereby reducing the risk of illness caused by those strains during the influenza season.

What side effects are possible with Fluquadri?

Possible Side Effects and Safety Information

The safety profile for Fluquadri is based on clinical trials and post-marketing surveillance data, categorized by frequency and the body system affected, according to regulatory standards.

Frequency-Classified Adverse Reactions

Adverse reactions are classified according to how often they have been reported in clinical studies. Reactions are typically mild to moderate and resolve within 1 to 3 days.

Classification Examples of Reactions
Very Common (ge 1/10) Injection site pain, headache, myalgia, fatigue, malaise, fever (in some populations)
Common (ge 1/100 to < 1/10) Injection site swelling/redness, shivering, nausea, vomiting, arthralgia
Rare/Not Known Serious adverse reactions (see below)

System-Organ-Class Safety Groupings

Side effects have been formally documented across various body systems, including General Disorders and Administration Site Conditions (e.g., fever, pain), Nervous System Disorders (e.g., headache, dizziness), and Musculoskeletal and Connective Tissue Disorders (e.g., myalgia, arthralgia).

Serious Adverse Reactions

A small number of clinically significant adverse reactions have been documented, primarily through post-marketing reporting, and are categorized as Rare or Frequency Not Known. These include Anaphylaxis (severe allergic reaction), Guillain-Barré Syndrome (GBS), and Convulsions.

Safety-Related Restrictions and Contraindications

Fluquadri is contraindicated for individuals with a history of severe allergic reaction (anaphylaxis) to any component of the vaccine or a previous dose of any influenza vaccine. Caution is advised for individuals with a history of GBS occurring within six weeks of a previous influenza vaccination, requiring careful assessment of risks versus potential benefits. Medical treatment for immediate management of anaphylaxis must be readily available at the time of administration.

Overdose and Emergency Response

Overdose and when to seek help

The official regulatory documentation for Fluquadri, which is an inactivated quadrivalent influenza vaccine, indicates that a specific toxicological overdose syndrome is not applicable to this product class. As a biological preparation, the regulatory labeling does not formally describe dose-escalation toxicity or specific symptom clusters associated with overdose.

Official Regulatory Stance on Overdose

Component Regulatory Statement
Documented Manifestations No specific toxicological signs or symptoms are formally described in the official labeling.
Antidote Information No specific antidote is documented or known for over-administration of this vaccine.
Supportive Measures Management of over-administration is defined as symptomatic and supportive treatment.

When to Seek Urgent Medical Help

If the suspected administration of an excessive volume of Fluquadri occurs, immediate medical attention is required, as mandated by regulatory documents. The official instruction is to contact a healthcare professional, hospital emergency department, or regional poison control centre immediately to ensure the patient receives clinical observation and appropriate care. This action is required to address any potential adverse reaction or clinical manifestation resulting from the deviation from prescribed use.

Therapeutic Uses of Fluquadri

Fluquadri is applied for the prophylaxis of seasonal influenza and its potentially serious outcomes. Annual vaccination contributes to a reduced risk of flu illnesses, hospitalizations, and the overall severity of illness.

Quadrivalent Prophylaxis Against Seasonal Influenza

The vaccine is used for the prevention of influenza disease caused by the four specific virus strains it contains. This supports individuals by helping avoid the sudden onset of severe systemic febrile illness and acute respiratory and pharyngeal manifestations, such as high fever, widespread body aches, and deep malaise.

A core purpose is easing the risk of severe health outcomes like pneumonia and subsequent hospitalization, a benefit particularly relevant for high-risk categories including older adults, young children, and individuals with chronic health conditions. The application of the vaccine assists with managing the risk of a potentially debilitating infection during periods of high viral circulation.


Quick Fact: Support Against Seasonal Stress

Fluquadri is used to help with conditions characterized by systemic imbalance and heightened physiological stress, which helps ease the overall symptom burden associated with the flu.

Eligibility and Restrictions for Use

The use of Fluquadri is officially defined by age restrictions, absolute prohibitions, and conditional rules for specific populations, as documented in regulatory labeling.

Eligibility Scope

Classification Rule (Official Regulatory Statement)
Approved for Use Persons 6 months of age and older.
Contraindicated Individuals with a history of severe allergic reaction (e.g., anaphylaxis) to any vaccine component, including egg protein, or to a previous influenza vaccine.
Use Not Established Children below the age of 6 months (safety and effectiveness have not been established).

Conditional Use and Restrictions

Use is subject to a careful risk/benefit assessment by a healthcare provider for the following populations, as the expected outcome or risk profile may be altered:

  • History of Guillain-Barré Syndrome (GBS): The decision to vaccinate must be based on careful consideration of the potential benefits and risks if GBS occurred within six weeks of a prior influenza vaccination.
  • Immunocompromised Persons: The expected immune response may not be obtained in individuals receiving immunosuppressive therapy or with altered immunocompetence.
  • Pregnancy and Lactation: Use is conditional. Fluquadri should be given only if clearly needed or following an assessment of the risks and benefits, as it is not known whether the vaccine is excreted in human milk.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The official regulatory documentation for Fluquadri specifies constraints related to its co-administration with certain medicinal products and conditions, primarily concerning the immune response, procedural requirements, and diagnostic test interference. The table below summarizes these documented interactions and the associated constraints.

Interacting Product Category Official Interaction Constraint/Requirement
Immunosuppressive Treatments (including corticosteroids) The expected immune response may be lower in individuals receiving immunosuppressive therapy or who are immunocompromised.
Other Injectable Vaccines The vaccine must not be mixed with any other vaccine in the same syringe or vial. If given simultaneously, the vaccines must be administered at different injection sites.
Anticoagulant Therapy / Bleeding Disorders Intramuscular injection must be given with caution to individuals on anticoagulant therapy or with bleeding disorders (e.g., thrombocytopenia) to avoid the risk of injection-site haematoma.
Serology Tests The vaccine may cause transient false positive results in specific serology tests, such as ELISA tests for antibodies against HIV1, Hepatitis C, and HTLV1. Confirmation via an appropriate Western Blot test may be necessary.

Older reports suggested potential hepatic clearance inhibition of medicines like phenytoin, theophylline, and warfarin following influenza vaccination; however, subsequent studies have not demonstrated undesirable effects related to this phenomenon. These documented interactions mandate that health professionals consider the altered immune response in specific populations and follow strict procedural rules for co-administration.

Mechanism of Action

Fluquadri is a quadrivalent influenza vaccine containing inactivated hemagglutinin and neuraminidase proteins derived from two influenza A subtypes and two influenza B lineages. The mechanism is initiated when professional antigen-presenting cells (APCs) recognize and internalize these viral protein antigens. The APCs subsequently migrate to draining lymph nodes where they process and present the antigens to naïve T-helper cells and B-lymphocytes. This interaction triggers the adaptive immune response cascade. Signaling pathways lead to the differentiation and proliferation of antigen-specific cells, resulting in the generation of both memory B and memory T cells. Furthermore, the cascade generates plasma cells which synthesize and secrete antigen-specific antibodies. This physiological modulation establishes an immune state prepared for secondary immune response upon subsequent viral exposure to the constituent influenza virus strains.

Dosage and Administration Information

Fluquadri is an inactivated quadrivalent influenza vaccine intended for active immunization against influenza disease caused by the virus strains contained in the vaccine. It is approved for use in persons 6 months of age and older.


Administration Method and Site

Fluquadri must be administered by intramuscular (IM) injection only. It should never be injected intravenously, intradermally, or subcutaneously.

  • Adults and Older Children (36 months and older): The preferred injection site is the deltoid muscle of the upper arm.
  • Infants (6 through 11 months): The preferred site is the anterolateral aspect of the thigh.
  • Younger Children (12 through 35 months): The injection may be given in the anterolateral aspect of the thigh or the deltoid muscle if there is adequate muscle mass.

Dosage and Schedule

The required dose and schedule vary based on the recipient's age and previous influenza vaccination history. All doses are typically given annually.

Age Group Dose Volume Schedule
9 years and older 0.5 mL Single dose
6 months through 8 years 0.5 mL One dose if previously vaccinated with influenza vaccine. Two doses (0.5 mL each), given at least four weeks apart, if no prior vaccination history or vaccination history is unknown.

Prior to administration, the vaccine should be visually inspected for particulate matter or discoloration. The vaccine vial or syringe must be shaken well before use.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Fluquadri


Evidence for Preventing Seasonal Influenza Illness

Research involving inactivated quadrivalent influenza vaccine ( QIV) formulations, such as Fluquadri, are studied using two main types of research. The first type is Randomized Controlled Trials ( RCTs), which are used to explore vaccine performance under controlled conditions (efficacy). The second type is Observational Studies, which monitor large groups of people during the flu season to examine patterns related to the occurrence of illness in the real world (effectiveness). These studies research examined the occurrence of laboratory-confirmed influenza illness caused by the four virus strains included in the annual vaccine formulation.

These studies describe patterns related to the occurrence of medically attended flu, and research examined outcomes related to severe health events. Research was studied for patterns of association between vaccine use and the occurrence of influenza-associated hospitalizations and admissions to the intensive care unit ( ICU). These observational studies help show what has been observed so far regarding changes in severe health events like pneumonia across large populations.

Evidence on Stimulating the Immune System (Immunogenicity)

One major focus of research was evaluated in settings exploring the vaccine's ability to trigger an immune response, called active immunisation. These trials typically measure Geometric Mean Titers ( GMTs) and Seroconversion Rates ( SCRs). These measurements reflect the levels of haemagglutination inhibition ( HI) antibodies produced against each of the four virus strains. Findings describe patterns where the antibody response achieved in study participants was measured against pre-established thresholds used as correlates for observed immune response.

Studies in Specific Age Groups and Populations

Research describes studies conducted across the entire licensed age range, starting from children 6 months and older up to older adults (65 years). Research examined the immune response patterns and patterns of effectiveness of the quadrivalent vaccine in these groups, including those with chronic health conditions.

What is Still Uncertain About the Research

Certain limitations and areas of uncertainty remain. When the predicted virus strains used in the vaccine do not precisely match the strains that actually circulate (known as strain mismatch), evidence suggests the observed effectiveness may be lower. Furthermore, data for certain groups remain insufficient, such as detailed data on effectiveness for all specific types of immunocompromised individuals. Follow-up in most studies is limited to a single influenza season.

Frequently Asked Questions (FAQ)

Common questions about Fluquadri (FAQ)

Q: Is it too late to get Fluquadri if flu season has already started?

A: According to official patient information, the vaccine can be administered until the spring, as the risk of catching influenza remains present during that period. A healthcare provider can offer guidance on the timing of vaccination for the current season.

Q: Is Fluquadri recommended every year?

A: Influenza vaccination is typically given annually. This is because the immunity (protection) gained from the vaccine may naturally decrease over the course of a year. Furthermore, the circulating strains of the influenza virus change from year to year, requiring an updated vaccine formulation like Fluquadri.

Q: Why is it important to get a new flu shot like Fluquadri each year?

A: Annual vaccination is generally discussed in the context of two factors, according to official guidance. First, the body's protection (immunity) from the shot may lessen throughout the year following vaccination. Second, the virus strains that the vaccine is designed to protect against are typically updated every year to match what experts predict will be circulating.

Q: Are there different formulations of Fluquadri for different age groups?

A: Fluquadri is consistently supplied as a 0.5 mL suspension for injection and is approved for persons 6 months of age and older. Differences in administration approach may be necessary based on a person's age and prior vaccination history, as outlined in official advisory committee recommendations.

Q: Is there a specific best time of year to get the Fluquadri vaccine?

A: Health authorities generally recommend receiving the vaccine before the influenza season begins in your area. This timing allows the immune system to build its protective response before virus activity peaks. A healthcare provider can offer guidance on the recommended timing for vaccination in a specific season.

Q: Can I drive immediately after getting the Fluquadri injection?

A: Official product information has documented reactions such as dizziness and syncope (fainting) following vaccination, which are categorized as Nervous System Disorders. Individuals who experience these symptoms should assess their own condition before driving or operating heavy machinery.

Q: Are there any activities I should avoid right after getting Fluquadri?

A: Rare reactions like syncope (fainting) have been reported in connection with the vaccination procedure itself. For this reason, procedures are often in place to ensure patient comfort and prevent injury related to fainting. Taking a moment to assess one's well-being is generally advisable before immediately resuming physical activities.

Q: Can Fluquadri protect against stomach flu or other non-influenza viruses?

A: No. Official guidance states that Fluquadri is specifically designed to protect against influenza disease (seasonal flu) caused by the four virus strains contained within the vaccine. It is not effective against other viruses, such as those that cause the stomach flu, or against strains of influenza not included in the vaccine.

Q: What percentage of people report pain at the injection site from Fluquadri?

A: Clinical study data indicates that injection site pain is one of the most frequently reported local reactions following vaccination. It is categorized as a Very Common reaction, meaning it has been reported by 10% or more of study participants.

Q: What happens if I receive a dose of Fluquadri when I am already feeling sick?

A: Regulatory warnings state that vaccination should be postponed if an individual is experiencing a moderate or severe acute illness, such as a fever or severe cold. It is generally advised that vaccination be postponed until recovery.

Q: Where can I find the official patient information leaflet for Fluquadri?

A: The official patient information leaflet, sometimes called the Consumer Medicine Information (CMI), is a regulatory document. You can usually find this information on the websites of national regulatory bodies (like the TGA, Medsafe, or the FDA).

Q: How long should I wait after an illness to get Fluquadri?

A: Official regulatory information advises that vaccination should be postponed if an individual is currently suffering from a moderate or severe acute illness. The recommendation is to postpone vaccination until an individual is fully recovered.

Q: Can Fluquadri be given at the same time as other vaccines?

A: Yes, regulatory guidance indicates that inactivated influenza vaccine can be given at the same time as other vaccines. Regulatory procedures specify that if given simultaneously, each vaccine should be administered at a separate injection site.

Q: Can pregnant women safely receive the Fluquadri vaccine?

A: Official guidance states that a healthcare provider can discuss the potential benefits and risks. Health authorities generally recommend influenza vaccination for pregnant women due to the known risks of influenza infection during pregnancy. The decision is based on a careful assessment of the potential benefits compared to any theoretical risks.

Q: Are there any specific supplements or vitamins that might interact with Fluquadri?

A: Official patient information recommends that individuals inform their healthcare provider about all medicines, vitamins, and supplements they are taking, including those bought without a prescription. This allows the provider to check for any possible known interference with the vaccine.

Q: How soon after getting Fluquadri does protection against the flu start?

A: The official documentation confirms the vaccine works by initiating an active immunization process to generate protective antibodies. While protection is not immediate, the body needs time to build this immune response. The expected time frame for antibody generation can be discussed with a healthcare provider.

Q: Is Fluquadri the same as the regular flu shot?

A: Fluquadri is an inactivated quadrivalent influenza vaccine. This means it protects against four different flu strains (two A and two B lineages). This quadrivalent type is now the common standard for the annual seasonal flu shot, offering wider coverage than older trivalent vaccines.

Q: Is it normal to feel tired after getting the Fluquadri shot?

A: Yes, feeling tired or unwell is noted in the official safety profile. Reactions like fatigue and general discomfort (malaise) are specifically listed as very common side effects experienced after vaccination.

Q: Can I take Fluquadri if I'm already taking common over-the-counter pain relievers?

A: Official guidance states that individuals should inform their healthcare provider about all medicines being taken, including over-the-counter pain relievers. The provider can advise if there are any known interactions or procedural requirements related to the timing of the dose.

Q: Can I take Fluquadri if I'm already taking blood pressure medication?

A: Individuals are advised to inform their healthcare provider about all prescription medicines being taken, including those for blood pressure. This allows the provider to review the medical profile and ensure there are no specific concerns related to the vaccine.

Q: Does Fluquadri contain mercury or thimerosal?

A: The official product information lists the vaccine's key components and traces of manufacturing residuals. While the active ingredients are the virus haemagglutinin antigens, the documentation does not list thimerosal or mercury compounds among the common traces. Residuals like formaldehyde and ovalbumin may be present.

Q: What is the difference between Fluquadri and other quadrivalent flu vaccines?

A: Fluquadri is an inactivated, split virion, egg-based quadrivalent vaccine. While all quadrivalent vaccines protect against the four strains, differences can exist in how they are manufactured (e.g., egg-based versus cell-based) or if they contain an adjuvant, which would be specified in their respective regulatory labels.

Q: What are the ingredients in the Fluquadri vaccine?

A: The active ingredients are the purified influenza virus haemagglutinin antigens from the four specified strains. The vaccine also contains other substances and may have traces of manufacturing residuals such as formaldehyde, ovalbumin (egg protein), and octoxinol-9.

Q: Is Fluquadri effective against all strains of the flu?

A: No. The vaccine is designed to protect against influenza disease caused by the four specific virus strains contained in the vaccine. Official information notes that the vaccine may not protect 100% of people and is not effective against all possible strains of influenza virus.

Q: Is there a maximum age limit for getting Fluquadri?

A: Official regulatory documents confirm that Fluquadri is approved for use in persons 6 months of age and older. The labeling does not specify an upper age limit for its use.

Q: Can Fluquadri be administered to individuals with chronic illnesses?

A: Vaccination of individuals with certain chronic illnesses, including chronic immunodeficiencies, is generally recommended. However, official warnings state that a lower antibody response may be obtained in immunocompromised individuals.

How should Fluquadri be stored and disposed of?

How to Store and Dispose of Fluquadri?

The storage and disposal of Fluquadri must adhere strictly to the conditions detailed in official regulatory documentation to maintain its stability.

Official Storage Requirements

Condition Type Requirement (Mandatory)
Temperature Range Store in the refrigerator between 2 C and 8 C.
Prohibited Environment Do not freeze; frozen vaccine must be discarded.
Protection Must be protected from light and kept in the original packaging.
Child Safety Keep the vaccine out of the sight and reach of children.

Disposal Instructions

Fluquadri must not be disposed of via wastewater or household waste. The medicine must not be used after the expiry date (EXP) stated on the carton. To discard unused or expired product, consult a pharmacist or nurse for guidance on appropriate pharmaceutical waste disposal according to local regulations.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Fluquadri found in:

A-Z Index: